XML 21 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Operating activities    
Net loss $ (104,081) $ (27,678)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation 4,582 4,520
Amortization of premium on investments 1,503 2,080
Unrealized loss (gain) on short-term investments 3 (436)
Gain on disposal of property and equipment 3 0
Stock-based compensation 27,608 24,256
Tax benefit on unrealized gain on available-for-sale securities 0 (371)
Realized gain on sales of available-for-sale securities (143) (37)
Changes in operating assets and liabilities:    
Accounts receivable 1,820 7,713
Prepaid expenses and other current assets 33 23
Other assets (1,657) 23
Accounts payable 184 (4,482)
Accrued liabilities (114) 4,231
Deferred revenue 4,121 14,733
Lease financing liability 474 690
Other long-term liabilities 337 388
Net cash provided by (used in) operating activities (65,327) 25,653
Investing activities    
Purchases of property and equipment (4,992) (1,106)
Proceeds from sale of property and equipment 5 0
Purchases of available-for-sale securities (102) (72)
Proceeds from sales of available-for-sale securities 21,109 4,298
Proceeds from maturities of available-for-sale securities 33,849 12,617
Net cash provided by investing activities 49,869 15,737
Financing activities    
Repayments of lease liability (302) (302)
Proceeds from follow-on offering, net of underwriting discounts and commission costs 471,205 0
Cash paid for payroll taxes on restricted stock unit releases (5,970) (2,242)
Proceeds from issuance of common stock 28,556 6,137
Payments of deferred offering costs (430) 0
Net cash provided by financing activities 493,059 3,593
Effect of exchange rate change on cash and cash equivalents (10) (24)
Net increase in cash and cash equivalents 477,591 44,959
Total cash and cash equivalents at beginning of period 173,782 153,324
Total cash and cash equivalents at end of period $ 651,373 $ 198,283